Repurposing Ivermectin for PKDL Treatment

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

January 1, 2025

Conditions
Post-kala-azar Dermal Leishmaniasis
Interventions
DRUG

Ivermectin 6 Mg Oral Tablet

A cumulative dose of 60 mg Oral Ivermectin monotherapy (12 mg/day) on five consecutive days (day 1 - day 5) for three consecutive months (180 mg in total)

DRUG

Miltefosine Oral Capsule

Oral Miltefosine monotherapy for 12 weeks. 50 mg in the morning and 50 mg in the evening with meal x 84 days (Total 100 mg/day)

Trial Locations (1)

1212

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka

All Listed Sponsors
lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT06251739 - Repurposing Ivermectin for PKDL Treatment | Biotech Hunter | Biotech Hunter